Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Tumor recurrence occurs in~20% of PTCs and some reach advanced stages. Promoter mutation in the telomerase reverse transcriptase (TERT) gene is identified to be a prognostic marker in PTC. However, the contribution of TERT promoter mutation to cancer progression in PTC patients is still not fully understood. In this study, we investigated the incidence of TERT promoter mutations and TERT protein expression and their association with clinicopathological outcomes in a large cohort of PTC samples using direct sequencing technology and immunohistochemistry. Furthermore, two PTC cell lines were utilized to investigate role of TERT mutations in mediating metastasis. Two promoter hotspot mutations C228T and C250T were identified in 18.0% (167/927) of our cohort and were significantly associated with poor 5 years disease-free survival and distant metastasis of PTC. TERT protein overexpression was noted in 20.1% of our PTC cohort and was significantly associated with poor prognostic markers such as older age, extrathyroidal extension and Stage IV tumors. A significant association was also found between TERT overexpression and epithelial-mesenchymal transition (EMT) markers. Functional analysis showed that TERT inhibition reduced cell growth, invasion, migration and angiogenesis in PTC via suppression of EMT in PTC cells. Our results suggest that TERT promoter mutation is an independent predictor of disease-free survival and might drive the metastasis, and downregulation of TERT could potentiate antitumor and antimetastatic activities in PTC.
Thyroid cancer is the most common endocrine cancer, and its incidence is increasing worldwide. 1 Among females, it is the second most common malignancy, after breast cancer, in Saudi Arabia, where it accounts for 9% of all cancers and 12% of all malignant cancers in females. 2 Among the several histological subtypes of thyroid cancer, papillary thyroid carcinoma (PTC) is the most common subtype, comprising 80%-90% of all thyroid cancers. 3 Although PTC is usually a well-differentiated thyroid cancer with favorable prognosis, the clinical behavior of PTC varies widely. 4, 5 Approximately 20% of PTCs demonstrate tumor recurrence, and some reach advanced stages. 6 Various clinicopathological variables, such as tall-cell variant, advanced stage, vascular invasion and nodal or distant metastasis, are related to aggressive behavior of PTC. 7, 8 However, the mechanisms underlying the aggressive behavior of some of the papillary thyroid carcinomas resulting in recurrence and metastases are not fully elucidated.
Telomerase reverse transcriptase (TERT) is a catalytic subunit of telomerase that plays a key role in cell immortality and tumorigenesis. 9 TERT promoter mutations, which lead to telomerase activation via upregulation of TERT mRNA expression, [10] [11] [12] [13] [14] [15] [16] [17] have been reported in various cancers such as bladder cancer, melanoma and anaplastic oligodendroglioma 13, 15, [18] [19] [20] including thyroid carcinomas. [21] [22] [23] [24] Two
Several recent studies have looked at TERT promoter mutations in thyroid cancer in various ethnic populations and have firmly established the frequent occurrence of this novel genetic alteration in human thyroid cancers, thus highlighting its important role in thyroid. 15, 25, 26 Some studies have suggested that these mutations are associated with more aggressive thyroid cancers, such as poorly differentiated carcinoma and anaplastic thyroid cancer (ATC). 22, 25 Such mutations are also detected in 12% of classic PTCs and are associated with an extremely poor prognosis when accompanied by the BRAF V600E mutation. 27 Others have shown strong association of TERT mutations with aggressiveness and metastatic spreading of thyroid malignancy. [22] [23] [24] [25] [26] 28 Metastasis is the most common cause of human cancer death and the underlying mechanism remains elusive, although evidence has recently accumulated that epithelialmesenchymal transition (EMT) has a critical role in cancer metastatic progression. 29, 30 It is incompletely understood how telomerase or TERT contribute to cancer progression. Given the important role of EMT in cancer invasion and metastasis, we sought to explore a link between TERT and EMT using PTC cell lines and the effect of targeting telomerase both in vitro and in vivo. Therefore, this study set out to determine the role of TERT promoter somatic mutations in the clinicopathological outcomes and prognosis in a large cohort of almost 1000 Middle Eastern PTC and correlate the mutations with protein expression via tissue microarray analysis. This allowed us to identify TERT mutation as a prognostic marker and suggesting potential role in PTC metastasis. Furthermore, functional analysis of relevant cell lines identified a link between TERT with EMT both in vitro and in vivo further suggesting the role of TERT mutations in mediating metastasis. 
Material and Method

DNA isolation
DNA was isolated from formalin-fixed, paraffin-embedded (FFPE) PTC tumor tissues using Gentra DNA isolation kit (Gentra, Minneapolis, MN, USA), following the manufacturer's recommendations as described previously. 31 
PCR and Sanger sequencing
The forward primer AGT GGA TTC GCG GGC ACA GA and reverse primer CAG CGC TGC CTG AAA CTC were used for identification of TERT mutation 228 C > T and 250 C > T. 22 PCR and Sanger sequencing were performed as described in Supporting Information, Methods. Reference sequence was downloaded from Genbank. Sequencing traces were analyzed using the Mutation Surveyor v4.04 (Soft Genetics, LLC, State College, PA).
Tissue microarray and immunohistochemical evaluation
All samples were analyzed in a tissue microarray (TMA) format. TMA construction was performed as described earlier. 32 Briefly, tissue cylinders with a diameter of 0.6 mm were punched from representative tumor regions of each donor tissue block and brought into recipient paraffin block using a modified semiautomatic robotic precision instrument (Beecher Instruments, Woodland, WI). Two cores of papillary carcinoma of the thyroid were arrayed from each case. Standard protocol was followed for immunohistochemistry (IHC) staining, details of which are provided in Supporting Information, Methods.
What's new?
Promoter mutation in the telomerase reverse transcriptase (TERT) gene has been identified as a prognostic marker in papillary thyroid carcinoma (PTC). However, the contribution of TERT promoter mutation to cancer progression in PTC patients is still not fully understood. Here, the authors analyzed TERT promoter mutation and protein expression in a cohort of almost 1000 Middle Eastern PTC patients. Altogether, the findings provide robust clinical and molecular evidence supporting the role of TERT alterations in PTC tumorigenesis and metastasis and offer a promising molecular target for developing therapeutic modalities.
Immunohistochemical scoring
H score was used to quantify TERT protein expression based on intensity and proportion of staining. The intensity of staining was scored from 0 to 3 (0, absent; 11, weak; 21, moderate; 31, strong), and the proportion of tumor cells staining for that particular intensity was recorded as 5% increments from a range of 0-100. The proportion was defined as the number of neoplastic cells with nuclear hTERT staining in each tissue microarray core, divided by the total number of neoplastic cells in the core. A final H score was assigned using the following formula:
. This H score ranges from 0 to 300. Two scores per tumor were analyzed in order to minimize the number of missing/uninterpretable spots. However, for the final score we used the higher of the two scores. X-tile plots were constructed for assessment of biomarker and optimization of cutoff points based on outcome as has been described earlier. 33 Based on X-tile plots, PTC cases were classified into two subgroups: those with H score 60 were defined as low expression and those with H score >60 were defined as over expression. Similarly, X-tile cutoffs were used to classify MMP-2, MMP-9 and Twist into high and low expression groups. E-cadherin and N-cadherin expression were classified as described previously.
34,35
Fluorescence in situ hybridization (FISH)
FISH assay for TERT gene amplification was performed on a tissue microarray (TMA) format. TMA was constructed as previously described. 36 The TERT/CEN5q FISH Probes were purchased from the Abnova (Walnut, CA, USA). The probe CEN5q was utilized as reference probe for enumeration. FISH on a TMA was performed as previously described. 37 Tissue samples were classified with a TERT and CEN5q ratio of 1.0 as normal; between 1.0 and 2.0 as having TERT gains; and 2 or over 2 as amplified.
Tissue culture experiments
The PTC cell line, BCPAP, was obtained from DSMZ, and TPC-1 was kindly provided by Dr Bryan McIver (Department of Endocrinology, Mayo Clinic, Rochester, Minnesota). Both cell lines were cultured in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin/streptomycin and 100 Units/ml Glutamine as described previously. 38 Both cell lines were authenticated in house using short tandem repeats PCR and the results (Supporting Information, Table 2 ) were in concordance with published data. 39 All experiments were performed using 5% FBS in RPMI 1640 media. The details of the antibodies used for immunoblotting are listed in Supporting Information, Table 3 .
Gene silencing using siRNA TERT siRNA and scrambled control siRNA were purchased from OriGene (Rockville, MD). Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for 6 hr following which the lipid and siRNA complex was removed and fresh growth medium was added. After 48 hr of transfection cells were used for immunoblotting and immunofluorescence analysis.
Immunofluorescence analysis
PTC cells grown on coverslips in 6-well plates were fixed with ice-cold 100% methanol followed by permeabilization with 0.2% Triton X-100, blocked with 5% horse serum in PBS solution and incubated with antibodies to TERT (1:50), E-cadherin (1:200), or N-cadherin (1:200) in buffer A (1% BSA, 0.1% Triton X-100, 10% horse serum in PBS solution) for 1 hr at 378C. Cells were then incubated with Alexa Fluor 488 goat anti-rabbit or Alexa Fluor 594 goat antimouse antibody and mounted using DAPI. The cells were visualized using Olympus BX63 fluorescence microscope.
Animals and xenografts study
Six-week-old nude mice were obtained from Jackson Laboratories (Bar Harbor, ME) and maintained in a pathogen-free animal facility at least 1 week before use. All animal studies were done in accordance with institutional guidelines. For xenograft study, TPC-1 cells (5 3 10 6 cells per mouse) were resuspended in serum-free medium with matrigel basement membrane matrix (BD Biosciences) at a 1:1 ratio (total volume 5 100 ll) and subcutaneously injected into the flanks of nude mice. After tumors grew to about 100 mm 3 , mice were treated intraperitoneally with BIBR1532 (10 and 20 mg/kg), twice a week for 30 days. The body weight and tumor volume of each mouse was monitored weekly. After 5 weeks treatment, mice were sacrificed and individual tumors were weighed, then snap-frozen in liquid nitrogen for storage.
Statistical analyses
Contingency table analysis and v 2 tests were used to study the relationship between clinico-pathological variables and TERT. Disease-free Survival curves were generated using the Kaplan-Meier method, with significance evaluated using the Mantel-Cox log-rank test. The limit of significance for all analyses was defined as p value of 0.05; two-sided tests were used in all calculations. The JMP10.0 (SAS Institute, Inc.,-Cary, NC) software package was used for data analyses.
RESULTS
Frequency and clinicopathological characteristics of TERT promoter mutations in PTC cohort
We first performed the sequencing analysis to examine the promoter mutations in primary tumor tissues of patients with PTC. Among 979 samples 52 samples failed to amplify the promoter region and were excluded from this study. Two hotspot promoter mutations were found in 167 cases, corresponding to 18.0% of overall cohort, common type was C228T (144/927, 15.5%) followed by C250T (24/927, 2.6%) ( Figure 1A ). These two promoter mutations occurred in mutually exclusive manner. Only one case harbored double mutations. The relative frequency among detected mutation is in line with available data in thyroid cancer. 22, 25, 40, 41 TERT mutations in this cohort is significantly associated with aggressive clinical parameters such as old age (p < 0.0001), Tall cell variant (p < 0.0001), extrathyroidal extension (p < 0.0001), lymphovascular invasion (p 5 0.0039), margin involvement (p < 0.0001), larger tumor size (T4) (p < 0.0001), lymph node involvement (p 5 0.0435), distant metastasis (p < 0.0001), higher stage (p < 0.0001) and poor clinical outcome (Table 1) .
TERT mutations predict poor outcome and might drive metastatic potential
We were particularly intrigued by the finding that TERT mutations is significantly associated with poor prognosis in Figure  1Ba) .
Cancer Genetics and Epigenetics
First, we set out to evaluate if the presence of TERT mutations is an independent prognostic predictor in PTC. We further analyzed the data, using cox proportional hazards regression model after adjusting for possible confounders of survival (Supporting Information, Table 4 ). Multivariate analysis showed that the presence of TERT mutation is indeed an independent prognostic factor (HR 5
We then asked whether this survival effect was independently driven by TERT mutations rather than coexisting driver mutations because in our previous study, BRAF mutations were seen in 60.0% of our PTC cases. 42 In this study, 69.5% (116/167) of TERT mutation-positive PTC samples had coexisting BRAF mutations. Specifically, we compared the clinical outcome of individuals with coexisting mutations in TERT and BRAF gene to those with mutations in BRAF gene only and found the former to be associated with significantly poorer outcome (p < 0.0001) (Figure 1Bb ).
The observations that TERT mutations are mostly observed in the context of BRAF gene mutation and their presence worsens the clinical outcome, raises the intriguing possibility that TERT mutations might not drive the initial oncogenesis of PTC but instead contribute significantly to its malignant evolution. In particular, distant metastasis, an already rare occurrence in PTC, was significantly more common in TERT mutation-positive individuals than those who lacked these mutations (p < 0.0001) ( Table 1) .
To test this hypothesis, we selectively analyzed an independent cohort of 72 PTC affected individuals with documented distant metastasis and found that frequency of TERT mutations in these individuals is 2.6 times as compared to the original unselected cohort (47.2% vs 18.0%, p < 0.0001, Figure 1C ). Based on these results that suggest a link between TERT mutations and distant metastasis, we set out to look for TERT mutations in distant metastases (brain, kidney and bone) from 19 PTC affected individuals for whom metastatic tissue samples were available to us. Strikingly, the frequency of TERT mutations was much higher in this subgroup (73.7%) than in the overall cohort (p < 0.0001) ( Figure 1C ). As we have previously highlighted the role of thyroglobulin (TG) gene mutations in distance metastasis, 42 we performed the previous analysis with and without TG mutations positive cases and the significance of these results stands true even without TG mutations cases which further highlights the independent role of TERT mutation in malignant evolution of PTC (Supporting Information, Figure 1 ).
TERT copy number alternation on FISH and its correlation with clinicopathological parameters
We also performed the FISH assay to examine the TERT copy number alteration in the primary tumor tissues of PTC cases. In our series of 979 PTC samples, FISH analysis was interpretable in 869 cases, TMA for 112 cases were nonrepresentative due to lack of tumor cells. Of the cases analyzed, copy number alterations, amplification/gain, were detected in 8/869 (0.92%) cases ( Supporting Information, Figure 2) . Amplification was seen in 5 (0.57%) cases while copy number gain was detected in 3 (0.35%) cases of PTC. Although the frequency of TERT gene amplification or gain was lower compared to other cancers, 43 we observed a significant association between TERT gene amplification/gain with TERT protein overexpression (p 5 0.0119) and distant metastasis (p 5 0.0143). Furthermore, TERT gene amplification/gain was identified to be significantly associated with poor disease-free survival (p 5 0.0016) (Supporting Information, Table 5 ). These results suggest that TERT copy number increase might play an important role in PTC progression in a small fraction of PTC patients.
TERT expression in PTC and its association with PTC clinicopathological features
To evaluate the effect of TERT expression on PTC progression and metastasis, we investigated the expression of TERT protein with 927 primary PTC tissue microarray. Immunohistochemical analysis could not be performed on 13 cases due to missing spots in the array. We observed TERT-positive staining in the nuclei of tumor cells ( Supporting Information, Figure 3 ). TERT overexpression was noted in 20.1% (184/914) of our PTC cohort.
TERT overexpression was positively correlated with TERT mutation (p < 0.0001). In addition, TERT overexpression was significantly associated with disease stage, particularly late stage (stage IV) (p < 0.0001). Moreover, TERT expression in metastatic PTC tumors was higher than in nonmetastatic specimens, although this was not statistically significant (p 5 0.0610). Correlation between TERT expression and clinicopathological characteristics are summarized in Supporting Information, Table 6 and show that increased TERT expression is correlated with older age (p < 0.0001), extrathyroidal extension (p < 0.0001), margin involvement (p 5 0.0152) and larger tumors (p < 0.0001). TERT overexpression was also associated with markers of invasion and migration, MMP-2 (p 5 0.0021) and MMP-9 (p 5 0.0036). Analysis of EMT markers revealed that TERT overexpression was directly associated with mesenchymal markers Twist (p 5 0.0342), a trend with N-cadherin (p 5 0.0554) and inversely associated with epithelial marker E-cadherin (p 5 0.0057). A brief summary of the scoring results in terms of extent of positively stained cells is provided in Supporting Information, Table 7 and Figure 4 .
More importantly, TERT was significantly associated with poor disease-free survival (p 5 0.0300). These findings indicate that TERT alteration plays a critical role in PTC progression and is a valuable biomarker for the disease.
Cancer Genetics and Epigenetics
Inhibition of TERT decreased progression of EMT in PTC cells
TERT has been shown to promote EMT in cancer cells, leading to the loss of epithelial adhesion molecule E-cadherin and induction of several mesenchymal markers such as N-cadherin and Vimentin. [44] [45] [46] Our clinical data showed that TERT overexpression was directly associated with the overexpression of N-cadherin and Twist and inversely associated with E-cadherin expression. Therefore, we sought to determine whether downregulation of TERT using specific inhibitor, BIBR1532 or TERT siRNA could inhibit progression of EMT in PTC cells. In our study, treatment of BIBR1532 markedly downregulated the expressions of TERT, Ncadherin, vimentin and Twist with an accompanying upregulation of E-cadherin expression in both PTC cells (Figure 2a) . Similar results were observed by immunofluorescence where downregulation of TERT using BIBR1532 increases the E-cadherin and decreases N-cadherin expressions in both PTC cells (Figure 2b ). Above data were further confirmed by TERT siRNA knockdown in PTC cells showing similar results (Figure 2c,d) .
Downregulation of TERT decreased PTC cell invasion, migration and angiogenesis
Mounting evidence indicates that overexpression of TERT is associated with EMT and metastasis. 44, 47 As EMT is one of the critical steps in cancer invasion and metastasis, 29, 30 we therefore investigated whether downregulation of TERT would inhibit invasion, migration and angiogenesis in PTC cells. As expected, inhibition of TERT using BIBR1532 significantly decreased invasion (Figure 3a ,b) and migration (Figure 3c ) of PTC cells. Furthermore, BIBR1532 treatment markedly downregulated MMP-2, MMP-9 and VEGF expressions in both PTC cells tested (Figure 3d ). To confirm these above findings, we silenced TERT with specific siRNA and assessed the protein expression of MMP-2, MMP-9 and VEGF in PTC cells. As shown in Figure 3e , silencing of TERT exhibited similar results of inhibiting TERT with BIBR1532. Silencing of TERT decreased MMP-2, MMP-9 and VEGF expressions in PTC cells. We also studied the effect of TERT inhibition in PTC cells on angiogenesis by tube formation assay. Tube formation of endothelial cells is one of the key steps of angiogenesis. 48 Incubation of HUVECs on matrigel with conditioned media (source of VEGF) of PTC cells resulted in the formation of elongated and tube like structures which were effectively reduced by conditioned media from BIBR1532 treated PTC cells (Figure 3f ). To further confirm these observations, we determined the secreted levels of VEGF and MMP-9 by ELISA experiment in BIBR1532 treated PTC cells. Decreased levels of VEGF and MMP-9 were observed in a dose-dependent manner in BIBR1532-treated PTC cells (Figure 3g,h ). Together, these findings suggest that BIBR1532 can significantly repress TERT expression and reduce PTC cell invasion, migration and angiogenesis by downregulating TERT target gene expression such as MMP-2, MMP-9 and VEGF.
Downregulation of TERT inhibited PTC cell growth in vitro and in vivo
Our clinical data showed that TERT overexpression was associated with a significant 5-year poor disease-free survival of 68.2% (p 5 0.0300) (Supporting Information, Table 6 ). Therefore, we wanted to investigate whether targeting TERT expression using BIBR1532 would be a viable therapeutic strategy to inhibit cell growth and induce apoptosis in PTC cells. We treated PTC cells with increasing doses of BIBR1532 for 48 hr to assess cell viability using MTT assay. As shown in Figure 4a , there was a significant (p < 0.05) dose-dependent inhibition of cell viability in both the cell lines. Next we have treated PTC cells with indicated doses of BIBR1532 and analyzed the colony number. Treatment of BIBR1532 significantly (p < 0.05) inhibited the clonogenicity of PTC cells as compared to untreated control (Figure 4b,c) .
To determine whether BIBR1532 induced cell inhibition was due to apoptosis, we treated PTC cells with increasing doses of BIBR1532 for 48 hr and analyzed the cells for apoptosis after dual staining with annexin V/PI by flow cytometry. As shown in Figure 4d , there was an increase in apoptosis following treatment with BIBR1532 in PTC cells confirming that this cell death was due to apoptosis. Next we investigated the effect of BIBR1532 on apoptotic protein markers in PTC cells by immunoblotting. As shown in Figure 4e , treatment of BIBR1532 successfully downregulated the expression of antiapoptotic proteins, Bcl-2, Bcl-xl and XIAP and cleavage of caspase-3 and PARP in both PTC cells lines. Inhibition of TERT significantly suppressed PTC cell growth in vitro. To further confirm these findings in vivo, we generated xenografts of TPC-1 cells in nude mice and treated them with two different doses of BIBR1532 (10 and 20 mg/ kg) for a period of four weeks. DMSO (0.1%, i.p) was served as vehicle control. After four weeks, the animals were sacrificed and their tumor weight was measured and proteins isolated. We found that treatment of BIBR1532 significantly suppressed tumor volume (Figure 5a ) and tumor weight (Figure 5b ) but had no effect on the body weight of mice (data not shown). Images of tumor showed that treatment of BIBR1532 caused shrinkage of tumor size (Figure 5c ). Finally, proteins isolated from tumors showed downregulation of TERT, N-cadherin, vimentin, Twist, MMP-2, MMP-9 and VEGF and upregulation of E-cadherin expression and cleavage of caspase-3 and PARP following treatment with BIBR1532 indicating that targeting TERT can regress PTC xenografts in nude mice (Figure 5d ).
DISCUSSION
Infinite capability of cancer cells to divide through maintenance of telomeres has been attributed mainly to the sustained expression of telomerase. Although telomerase is upregulated in over 90% of human cancers, 9,49 a definite mechanism for its cancer-specific activation has remained unclear. The detection of the activating somatic mutations in the promoter of the TERT gene has provided an insight into the possible cause of telomerase regeneration. The mutations first detected in melanoma seem to be recurrent in many cancer types. 13, 50 In this study, we investigated and validated the role of TERT promoter somatic mutations in a large cohort of primary PTC.
In this study, we found frequency of the TERT promoter mutations is 18.0% which is consistent with previous reports. 22, 25, 40, 41 Major finding is the association of the TERT promoter mutations with adverse markers of PTC prognosis, most notably, distant metastasis and the fact that TERT mutation is an independent prognostic marker for PTC patients. Our findings are similar to study by Xing et al. who analyzed 507 PTC cases and found that mutation was associated with significant poor disease-free survival. 27 Similarly, Bullock et al. found a poor disease-free survival in TERT mutated cases in their cohort of 80 cases. 51 However, another study by Qasem et al. failed to show any significant association between TERT alteration and survival. 41 Several previous studies have established the correlation between PTC and aggressive marker but this is the largest cohort to analyze TERT mutation in PTC. 22, 25 Furthermore, many previous studies have linked the aggressiveness effect of TERT mutation to its co-existence with BRAF mutation in PTC 40, 51 but in our study we have shown that prognostic effect is independent of the presence of BRAF mutations.
In our study, TERT mutations appear to exert significant effect on the evolution of PTC. The observation that most of TERT mutation positive PTC samples also harbored mutations in BRAF gene suggests that TERT mutations might not act as driver mutations per se. However, we show that these TERT mutations were nonetheless associated with significantly worse clinical outcome than were BRAF mutation in the absence of TERT mutations. This is consistent with a role of TERT mutation in driving the evolution of PTC to a more aggressive phenotype. Our findings also highlight the above notion since, TERT mutations appear to be enriched in metastatic PTC compared to the localized PTC in our cohort.
Metastasis in PTC is a rare event, as can be observed from our own cohort, where only 72 (7.3%) of 979 cases were diagnosed with distant metastasis. Therefore, identification of genetic markers and biological process as the basis of the metastatic spreading of these tumor help in improving current prognostic capacity in the diagnosis of PTC. The fact that most of the cases harboring TERT mutation showed over expression of TERT protein expression is indicative that increased TERT expression as a sequence of mutation may play a role in tumor growth and that TERT protein expression could be used as a marker of adverse outcome in PTC.
Thus, we present very important clinical evidence that TERT mutations promote PTC aggressiveness and metastasis. Both our in vitro and in vivo assays supported the notion. Altered TERT expression affected the ability of migration and invasion of PTC cell lines.
Cancer metastasis is a complex process involving a multitude of cellular and molecular mechanisms which are yet to be fully elucidated. 52, 53 EMT is a critical process, contributing to tumor metastasis by providing epithelial derived tumor cells with the ability of increased migration and invasiveness. 54, 55 In this study, we found that cell lines with high TERT expression show mesenchymal phenotype. Elevated TERT expression could contribute to acquisition of the EMT phenotype by upregulating mesenchymal markers N-cadherin and Vimentin and downregulating the epithelial cell maker E-cadherin, whereas downregulation of TERT could cause the opposite which highlight the correlation between TERT expression and cancer cell EMT in human PTC cells.
Other important markers involved in tumor cell invasion angiogenesis and metastasis are MMP-2, MMP-9 and VEGF. Our functional analysis showed that downregulation of TERT inhibited MMP-2, MMP-9 and VEGF. Thus, these results suggest that the downregulation of TERT could potentiate antitumor and antimetastatic activities in PTC partly through downregulation of MMPs.
Altogether, this study provides robust clinical and molecular evidence supporting the role of TERT alterations in PTC tumorigenesis and metastasis. Our study not only indicates a very important molecular mechanism of PTC progression and metastasis but also offers a promising molecular target for developing therapeutic modalities to control the progression and metastasis of PTC.
AUTHOR CONTRIBUTIONS
Al-Kuraya KS participated in study design, data analysis and interpretation and manuscript drafting. Bu R, Siraj AK, Divya SP and Parvathareddy SK participated in experiment design, data acquisition, data analysis and manuscript preparation. Kong Y contributed to the experiment design and data analysis. Al-Rahseed M, Al Obaisi KAS and Victoria IG performed the experiments. Al-Sobhi SS, Al-Dawish M and Al-Dayel F participated in data collection and data analysis.
